NMNesrine Aly Mohamed

Nesrine Aly Mohamed

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nesrine Aly Mohamed has a total of 67 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Low frequency of CD4+CD25highFOXP3+ T regulatory cells in Egyptian patients with chronic spontaneous urticaria

    by Mohamed Elshayeb, Mohamed Farres, Nermine Melek, Asmaa Mostafa, Salah Galal, Nesrine Mohamed, Eman Ahmed

    Hronic urticaria is a prevalent disabling dermatological disease. About 90%, are considered idiopathic and referred to as chronic spontaneous urticaria (CSU), and nearly half of them are likely to have autoimmune mechanisms. Regulatory T cells play a substantial role to prevent autoimmune diseases. Subsets of Tregs expressing the CD4+CD25high and forkhead-box-P3 (FOXP3) transcription factor, crucial for their development and function, are best characterized in maintenance of self-tolerance. The objective of this study was the analysis of peripheral CD4+CD25highFOXP3+(T regs) frequency in chronic spontaneous urticaria; and its possible association with autologous serum skin test (ASST). Fifty chronic spontaneous urticaria patients (25 with positive ASST and 25 with negative ASST) and 20 healthy controls were enrolled in this study. The frequency of CD4+CD25highFOXP3+ (T regs) was analyzed by flow cytometry. A Significant decrease in peripheral blood CD4+CD25highFOXP3+ T regs% was detected in CSU patients in comparison to healthy individuals (median [IQR], 1.47% [0.71–3.12] vs 1.79% [1.15–4.00]; P = 0.05). When ASST positive patients were compared with ASST negative patients, no significant difference was found in percentage of T regs, (P=0.112). In conclusion our data provided further insights into CSU pathogenesis. Reduced frequency of CD4+CD25highFOXP3+(Tregs) in patients with urticaria, support the notion that CSU is an immune mediated disease and may help researchers to develop a novel immunotherapy strategy.


  • Corrigendum to The influence of interferon-β supplemented human dendritic cells on BCG immunogenicity

    by Sally A.F. El-Sahrigy, Azza M.O. Abdel Rahman, Dalia Y. Samaha, Sally M. Saber, Hala A. Talkhan, Ghada A. Ismail, Essam M. Ibraheem, Emad M. Riad, Nesrine A. Mohamed


  • Interleukin-34 as a marker for subclinical proliferative lupus nephritis

    by Asmaa Sm Abdel-Rehim, Nesrine A Mohamed, Marwa M Shakweer

    Lupus nephritis (LN) is an ominous manifestation of systemic lupus erythematosus (SLE). Clinical renal affection is present in about 70% of lupus patients, and more patients have histological evidence of renal involvement without clinical manifestations. This study aimed to investigate the potential role of serum interleukin-34 (IL-34) as an early marker for the detection of silent LN. Thirty-three lupus patients with silent LN (group I), 37 patients with clinical LN (group II) and 20 controls were included. The SLE Disease Activity Index (SLEDAI), IL-34, anti-dsDNA antibodies and renal biopsy were assessed in all patients. Serum IL-34 levels were significantly higher in all lupus patients compared to healthy controls (p < 0.001) and showed a significant positive correlation with SLEDAI score. SLE patients with positive anti-dsDNA antibodies had more active disease according to SLEDAI and higher levels of IL-34 than those with negative anti-dsDNA antibodies. In both studied groups, serum IL-34 levels were significantly higher in patients with proliferative LN (class III and class IV) than those with non-proliferative lupus (class II and class V) and controls. Yet, in both groups, IL-34 was not useful in differentiating active from chronic renal affection. In lupus patients with insignificant proteinuria, serum levels of IL-34 distinguished the different histological classes of subclinical LN. Serum IL-34 may be used as a surrogate marker for early renal affection in silent LN, especially the proliferative type.


  • Influence of vitamin D receptor gene FokI and ApaI polymorphisms on glucocorticoid response in patients with asthma

    by Nesrine A. Mohamed, Asmaa S. Abdel‐Rehim

    Background: Glucocorticoid (GC)‐resistant asthma, a complex disease phenotype, has a high morbidity and mortality and takes up a disproportionate share of healthcare costs. The aim of this work was to assess serum 25‐hydroxyvitamin D (25(OH)VD) levels in steroid‐resistant, steroid‐sensitive patients with asthma and in healthy controls, and to investigate the association between the vitamin D receptor gene (VDR) FokI and ApaI polymorphisms and GC resistance in patients with asthma.Methods: This case‐control study included 70 patients with severe bronchial asthma and 30 apparently healthy controls. Atopic status was determined by skin‐prick test reaction to the most common locally‐encountered allergens. A GC reversibility test was performed to differentiate between GC‐sensitive and GC‐resistant asthma. For all subjects, analysis of the VDR FokI and ApaI polymorphisms by polymerase chain reaction–restriction fragment length polymorphism (PCR‐RFLP) and measurement of serum 25(OH)VD levels by enzyme‐linked immunosorbent assay (ELISA) were performed.Results: The frequencies of FokI polymorphism genotypes and alleles differed significantly between patients with asthma and controls. The frequencies of the TT genotype and T allele carriers were significantly higher among patients with asthma than among controls, and also among GC‐resistant patients with asthma than among GC‐sensitive patients with asthma. Additionally, serum 25(OH)VD levels differed significantly among the 3 VDR FokI polymorphic genotypes in GC‐resistant patients with asthma; the highest level was detected in the TT genotype. No significant differences in ApaI were found.Conclusion: We found a possible association between the FokI T allele and GC resistance in patients with asthma. Variations in VDR FokI might also play a role in 25(OH)VD levels.


  • Open Access

    Soluble and membranous endothelial protein C receptor in systemic lupus erythematosus patients: Relation to nephritis

    by Asmaa A. Shaaban, Nadia A. Elkadery, Hebatallah A. El-Shamy, Rana A. El-Hilaly, Nadia G. El-Hefnawy, Nesrine A. Mohamed


  • The immunomodulatory role of zinc in asthmatic patients

    by Nesrine A Mohamed, Marwa Rushdy, Asmaa S.M. Abdel-Rehim


  • The influence of interferon-β supplemented human dendritic cells on BCG immunogenicity

    by Sally A.F. El-Sahrigy, Azza M.O. Abdel Rahman, Dalia Y. Samaha, Nesrine A. Mohamed, Sally M. Saber, Hala A. Talkhan, Ghada A. Ismail, Essam M. Ibraheem, Emad M. Riad


  • Transient elastography as a noninvasive assessment tool for hepatopathies of different etiology in pediatric type 1 diabetes mellitus

    by Zeinab A. Elkabbany, Nancy S. Elbarbary, Eman A. Ismail, Nesrine A. Mohamed, Dina Ragab, Shereen Abdel Alem, Yasmine M. Ezzat, Sarah S. Maurice, Noha U. Hashem


  • Open Access

    Characterization of differential antibody production against hepatitis C virus in different HCV infection status

    by Mona Rafik, Salwa Bakr, Dina Soliman, Nesrine Mohammed, Dina Ragab, Walid Abd ElHady, Nancy Samir

    The Centers for Disease Control and Prevention (CDC) issued an update on hepatitis C virus (HCV) testing approach, in which it omitted the use of recombinant immunoblot assay (RIBA) in the diagnostic algorithm and recommended that future studies are needed to evaluate the performance of HCV testing without RIBA. As Egypt has the highest prevalence of HCV worldwide, we aimed to evaluate the value of RIBA in HCV testing in a high prevalence population. Our objective was to clarify whether enzyme linked immunosorbent assay (ELISA) anti-HCV signal-to-cutoff (S/CO) ratios were able to discriminate true positive from false positive anti-HCV antibody status and to evaluate the role of RIBA in solving this problem which may lead to a redefined strategy for diagnosis of HCV infection. Our second objective was to elucidate the effects of different HCV peptides of both structural and non-structural proteins on the humoral immune response to HCV infection. The current study drew results from 167 individuals divided into three groups: Group I: included 77 HCV antibody positive (ELISA) high risk health care workers (HCW), Group II: included 56 presumably uninfected individuals who showed normal liver enzymes, negative HCV RNA and were asymptomatic. Their ELISA HCV antibody S/C ratio ranged from 0.9 to <5. Group III: included 34 patients enrolled from outpatient clinics of Ain Shams Hospital with persistent viral replication, elevated liver enzymes, and chronic HCV related liver disease. All study participants were assessed for the presence of anti-HCV antibodies by 3rd generation ELISA which was confirmed by RIBA. Interpreting the results of both ELISA and RIBA together, false positive results were highly significantly increased in HCW when compared with the other two groups. Indeterminate and false negative results were only found in the presumably uninfected group. For differentiated antibody responses by RIBA, chronic HCV cases had the highest frequency of positive antibody response to core peptides while the presumably uninfected group had the lowest. Antibody response to E2 was found less frequently in chronic cases than Core 1, Core 2 and NS3. The specific antibody response to the different HCV peptides showed the same distribution of frequencies in both chronic HCV cases and the presumably uninfected individuals with the chronic cases having the highest frequencies. This distribution was different from the HCW. The most evident difference was the reaction towards NS3 which was the highest antibody producing peptide in chronic HCV and presumably uninfected individuals whereas in HCW Core1 was the highest. The HCV antibody immunoblot assay (RIBA) is still necessary for the detection of false positive cases which can occur quite frequently in countries of high prevalence as Egypt. Indeterminate RIBA results indicate a waning antibody response in elderly individuals who recovered from previous or distant HCV infection.


  • Open Access

    Influence of glucocorticoid receptor gene NR3C1 646 C>G polymorphism on glucocorticoid resistance in asthmatics: a preliminary study

    by Nesrine A. Mohamed, Asmaa S.M. Abdel-Rehim, Mohamed Nazmy Farres, Hedya Said Muhammed

    Background: Glucocorticoid receptor gene polymorphism (NR3C1 646 C>G) may play an important role in the development of severe bronchial asthma and resistance to glucocorticoids (GCs). Objective: The aim of the present study was to determine the relation between the 646 C>G polymorphism of the glucocorticoid receptor gene (NR3C1) and resistance to GCs with development of severe bronchial asthma. Material and methods: This case-control study included 40 patients with severe bronchial asthma and 20 apparently healthy controls. Atopic status was determined by skin prick test reaction to the most common locally-encountered allergens. GCs reversibility test was performed to differentiate between GCs sensitive and GCs resistant asthma. For all subjects, analysis of the glucocorticoid receptor gene polymorphism (NR3C1 646 C>G) was done using polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP). Results: The frequencies of NR3C1 646 C>G genotypes and alleles differed significantly between asthmatic patients and controls. The frequencies of the CC genotype and C allele carriers were significantly higher among asthmatics than among controls, and also among GCs sensitive asthmatics than among GCs resistant asthmatics. However, NR3C1 646 C>G genotypes and alleles frequencies did not differ significantly according to the atopic status in asthmatics. Conclusions: The too small sized of the investigated groups is a shortcoming of this study. Nevertheless, the observed variations demonstrate a marked association of NR3C1 646 C>G CC genotype with the development of bronchial asthma and a higher frequency of the C allele among GCs sensitive asthmatics. Large-scale studies are required to investigate the association between polymorphisms of the NR3C1 gene and GCs resistance among asthmatic patients.